BACKGROUND: Pulsatile ventricular assist devices (VADs) are used to bridge adults with end-stage heart disease to transplantation. A combination of external implantable pulsatile and continuous-flow external mechanical support now can be used to bridge pediatric patients with end-stage cardiomyopathy to orthotopic heart transplantation (OHT). METHODS: We reviewed consecutive pediatric patients with cardiomyopathy (n = 28) who required mechanical cardiac support from July 1995 to February 2001. All were OHT candidates with severe hemodynamic compromise despite maximal medical support. We excluded from this series patients who had undergone cardiotomy. RESULTS: Nineteen patients received support from external continuous-flow devices, either with extracorporeal membrane oxygenation or with centrifugal VADs, and 9 patients received pulsatile support. Nineteen of 28 (68%) patients were successfully bridged to transplant (17) or weaned (2) from their devices after recovery. Of the patients successfully bridged to transplant or recovery, 89% are alive to date. Univariate analysis revealed that a lower bilirubin concentration after 2 days of support was associated with a favorable outcome (p = 0.006). As expected, the patients with pulsatile VADs had significantly higher rates of extubation and oral feeding. CONCLUSION: Pulsatile and continuous-flow devices can complement each other to significantly extend the lives of a wide range of pediatric patients with severe cardiomyopathies.
BACKGROUND: Pulsatile ventricular assist devices (VADs) are used to bridge adults with end-stage heart disease to transplantation. A combination of external implantable pulsatile and continuous-flow external mechanical support now can be used to bridge pediatric patients with end-stage cardiomyopathy to orthotopic heart transplantation (OHT). METHODS: We reviewed consecutive pediatric patients with cardiomyopathy (n = 28) who required mechanical cardiac support from July 1995 to February 2001. All were OHT candidates with severe hemodynamic compromise despite maximal medical support. We excluded from this series patients who had undergone cardiotomy. RESULTS: Nineteen patients received support from external continuous-flow devices, either with extracorporeal membrane oxygenation or with centrifugal VADs, and 9 patients received pulsatile support. Nineteen of 28 (68%) patients were successfully bridged to transplant (17) or weaned (2) from their devices after recovery. Of the patients successfully bridged to transplant or recovery, 89% are alive to date. Univariate analysis revealed that a lower bilirubin concentration after 2 days of support was associated with a favorable outcome (p = 0.006). As expected, the patients with pulsatile VADs had significantly higher rates of extubation and oral feeding. CONCLUSION: Pulsatile and continuous-flow devices can complement each other to significantly extend the lives of a wide range of pediatric patients with severe cardiomyopathies.
Authors: Ravi R Thiagarajan; Stephen J Roth; Steven Margossian; Andrew S Mackie; Ellis J Neufeld; Peter C Laussen; Joseph M Forbess; Elizabeth D Blume Journal: Intensive Care Med Date: 2003-04-29 Impact factor: 17.440
Authors: Paul Monagle; Anthony K C Chan; Neil A Goldenberg; Rebecca N Ichord; Janna M Journeycake; Ulrike Nowak-Göttl; Sara K Vesely Journal: Chest Date: 2012-02 Impact factor: 9.410
Authors: F Schmidt; T Jack; M Sasse; T Kaussen; H Bertram; A Horke; K Seidemann; P Beerbaum; H Koeditz Journal: Pediatr Cardiol Date: 2015-06-07 Impact factor: 1.655
Authors: Michael T Griffin; Matthew F Grzywinski; Hannah J Voorhees; Marina V Kameneva; Salim E Olia Journal: ASAIO J Date: 2016 Sep-Oct Impact factor: 2.872
Authors: Brigitte Stiller; Julia Lemmer; Frank Merkle; Vladimir Alexi-Meskishvili; Yuguo Weng; Michael Hübler; Andreas Koster; Thorsten Drews; Peter E Lange; Roland Hetzer Journal: Intensive Care Med Date: 2004-07-22 Impact factor: 17.440